# SapphireDerm Price Discipline Analysis

**Analysis Date:** July 27, 2025

## EPV Discipline Framework
- **EPV Base Case Equity:** $11,194,168
- **Strategic Premium:** 12.5%
- **Maximum Disciplined Price:** $12,593,439

## Price Discipline vs EV/EBITDA Multiples

| Multiple | Enterprise Value | Equity Value | Premium vs EPV | Discipline Check |
|----------|------------------|--------------|----------------|------------------|
| 8.0x | $17,688,000 | $16,838,000 | +50.4% | ❌ FAIL |
| 8.5x | $18,793,500 | $17,943,500 | +60.3% | ❌ FAIL |
| 9.0x | $19,899,000 | $19,049,000 | +70.2% | ❌ FAIL |
| 9.5x | $21,004,500 | $20,154,500 | +80.0% | ❌ FAIL |
| 10.0x | $22,110,000 | $21,260,000 | +89.9% | ❌ FAIL |
| 10.5x | $23,215,500 | $22,365,500 | +99.8% | ❌ FAIL |

## Investment Decision Framework

**Disciplined Range:** Up to 12% premium over EPV Base Case acceptable for strategic value.

**Recommended Action:**
- **DEFER** - All tested multiples exceed EPV discipline threshold
- Renegotiate price or identify additional strategic value
